David A. Leiman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David A. Leiman has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
Alice Parish
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, 27710, USA
5 shared publications- Amit Patel
Division of Gastroenterology Durham Veterans Affairs Medical Center and Duke University Durham North Carolina USA
5 shared publications - Donna Niedzwiecki
Duke Cancer Institute Biostatistics, Duke University Medical Center, Durham, North Carolina
4 shared publications Priya Kathpalia
Division of Gastroenterology, University of California, San Francisco , San Francisco, CA
4 shared publicationsRichard K. Wood
Division of Gastroenterology, Duke University School of Medicine, Durham, USA
4 shared publications- Shai Posner
Albany Gastroenterology Consultants , Albany, NY , USA
4 shared publications
Latest Publications
- 12 June 2026
- Published by Springer Nature in Dysphagia
Dysphagia in Older Adults with Malignant Brain Tumors: Results of a National Study of Medicare Beneficiaries
The risk of swallowing dysfunction increases with age and is associated with underlying neurological conditions. However, the prevalence of dysphagia and its impact on outcomes among older adults with brain tumors is unknown. We aimed to determine the prevalence of dysphagia among patients ≥ 65 years with brain tumors and evaluate the relationship between dysphagia and outcomes, including healthcare utilization and survival, within this group. We hypothesized that the rates of dysphagia would be higher among those with brain cancer compared to those with solid organ cancer, and that nutrition via enteral access would not improve survival. Using a Medicare 5% limited dataset (2013-2018), we identified beneficiaries (≥ 65 years) with malignant brain tumors and measured the prevalence of dysphagia by ICD-9/10 codes. We compared outcomes and rates of dysphagia-related care among beneficiaries with primary malignant brain tumors (PMBTs) and those with solid tumors (with and without brain metastases) using current procedural terminology (CPT) codes. Beneficiaries with coexisting disorders predisposing to dysphagia were excluded. Kaplan Meier curves were used to estimate survival. Dysphagia was more prevalent among beneficiaries with PMBTs (11.0%) compared to those with solid tumors with (7.9%) and without (4.4%) brain metastases (p < 0.01). The presence of dysphagia was significantly associated with hospitalization (p < 0.01), use of gastrointestinal (GI) services (p < 0.01) and decreased survival: 75% of those with dysphagia survived 319 days post-cancer diagnosis (95% CI: 301, 332), versus 1082 days post-cancer diagnosis for those without dysphagia (95% CI: 1064, 1104) (p < 0.001). Among those with PMBTs, enteral access was not associated with an improvement in survival (p = 0.08). Dysphagia is prevalent among older adults with brain tumors (primary and metastatic) and is associated with increased mortality risk. Enteral access placement among those with PMBTs and dysphagia did not demonstrate improvement in survival.
- 12 June 2026
- Published by Springer Nature in Dysphagia
Dysphagia in Older Adults with Malignant Brain Tumors: Results of a National Study of Medicare Beneficiaries
The risk of swallowing dysfunction increases with age and is associated with underlying neurological conditions. However, the prevalence of dysphagia and its impact on outcomes among older adults with brain tumors is unknown. We aimed to determine the prevalence of dysphagia among patients ≥ 65 years with brain tumors and evaluate the relationship between dysphagia and outcomes, including healthcare utilization and survival, within this group. We hypothesized that the rates of dysphagia would be higher among those with brain cancer compared to those with solid organ cancer, and that nutrition via enteral access would not improve survival. Using a Medicare 5% limited dataset (2013-2018), we identified beneficiaries (≥ 65 years) with malignant brain tumors and measured the prevalence of dysphagia by ICD-9/10 codes. We compared outcomes and rates of dysphagia-related care among beneficiaries with primary malignant brain tumors (PMBTs) and those with solid tumors (with and without brain metastases) using current procedural terminology (CPT) codes. Beneficiaries with coexisting disorders predisposing to dysphagia were excluded. Kaplan Meier curves were used to estimate survival. Dysphagia was more prevalent among beneficiaries with PMBTs (11.0%) compared to those with solid tumors with (7.9%) and without (4.4%) brain metastases (p < 0.01). The presence of dysphagia was significantly associated with hospitalization (p < 0.01), use of gastrointestinal (GI) services (p < 0.01) and decreased survival: 75% of those with dysphagia survived 319 days post-cancer diagnosis (95% CI: 301, 332), versus 1082 days post-cancer diagnosis for those without dysphagia (95% CI: 1064, 1104) (p < 0.001). Among those with PMBTs, enteral access was not associated with an improvement in survival (p = 0.08). Dysphagia is prevalent among older adults with brain tumors (primary and metastatic) and is associated with increased mortality risk. Enteral access placement among those with PMBTs and dysphagia did not demonstrate improvement in survival.
- 14 May 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (9) , 810-816
Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use
Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) use is associated with delayed gastric emptying. It is unknown whether GLP-1RAs affect esophageal motility. We aimed to assess the relationship between GLP-1RA use and esophageal function test results. Methods: Patients with type 2 diabetes undergoing high-resolution manometry (HRM) between December 2022 and October 2024 were retrospectively evaluated, comparing cases with controls (on vs. off GLP-1RA). HRM diagnoses per the Chicago Classification 4.0 and reflux testing results were collected. Patients with prior foregut surgery and known conditions associated with dysmotility (eg, scleroderma) were excluded. Comparisons were performed using χ 2 and Mann-Whitney U tests for categorical and continuous measures, respectively. Results: There were 132 patients assessed and most (29/42, 69.0%) cases were female. Semaglutide was the most commonly used GLP-1RA (24, 57.1%) among cases, and the median A1c was the same (6.6%) for both cases and controls. Most GLP-1RA users (27, 64.3%) had a normal HRM and there was no significant difference ( P =0.07) in overall HRM diagnoses between cases and controls. There was no association ( P =0.51) between GLP-1RA type or dose and esophageal motility diagnoses. Among those undergoing formal reflux testing, there was no difference in detected rates of gastroesophageal reflux disease ( P =0.51) between cases and controls. Conclusion: We did not detect a statistically significant impact of GLP-1RA use on esophageal function assessed by formal testing among patients with type 2 diabetes. These results suggest that patients may continue GLP-1RAs when undergoing esophageal testing and are not at significantly increased risk for impacts on esophageal motility diagnosis compared with nonusers.
- 14 May 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (9) , 810-816
Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use
Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) use is associated with delayed gastric emptying. It is unknown whether GLP-1RAs affect esophageal motility. We aimed to assess the relationship between GLP-1RA use and esophageal function test results. Methods: Patients with type 2 diabetes undergoing high-resolution manometry (HRM) between December 2022 and October 2024 were retrospectively evaluated, comparing cases with controls (on vs. off GLP-1RA). HRM diagnoses per the Chicago Classification 4.0 and reflux testing results were collected. Patients with prior foregut surgery and known conditions associated with dysmotility (eg, scleroderma) were excluded. Comparisons were performed using χ 2 and Mann-Whitney U tests for categorical and continuous measures, respectively. Results: There were 132 patients assessed and most (29/42, 69.0%) cases were female. Semaglutide was the most commonly used GLP-1RA (24, 57.1%) among cases, and the median A1c was the same (6.6%) for both cases and controls. Most GLP-1RA users (27, 64.3%) had a normal HRM and there was no significant difference ( P =0.07) in overall HRM diagnoses between cases and controls. There was no association ( P =0.51) between GLP-1RA type or dose and esophageal motility diagnoses. Among those undergoing formal reflux testing, there was no difference in detected rates of gastroesophageal reflux disease ( P =0.51) between cases and controls. Conclusion: We did not detect a statistically significant impact of GLP-1RA use on esophageal function assessed by formal testing among patients with type 2 diabetes. These results suggest that patients may continue GLP-1RAs when undergoing esophageal testing and are not at significantly increased risk for impacts on esophageal motility diagnosis compared with nonusers.
- 10 February 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (10) , 2401-2410
Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease
INTRODUCTION: Potassium competitive acid blockers (PCABs) are superior to proton pump inhibitors (PPIs) for healing of Los Angeles (LA) class C/D erosive esophagitis and are approved for nonerosive gastroesophageal reflux disease (GERD) given their efficacy measured by heartburn-free days. However, they are more expensive than PPIs. We estimated the cost-effectiveness of PCABs compared with PPIs for the management of GERD. METHODS: A decision tree was constructed for the base case of a patient with GERD. We tested scenarios in which nonerosive reflux disease, LA A/B, or LA C/D esophagitis was present, comparing PCABs with PPIs as first-line therapy, including step up therapy and/or class switching if symptoms persisted. Using publicly available cost estimates, quality-adjusted life years (QALYs) were compared using a willingness-to-pay threshold of $100,000/QALY from a societal perspective at 6 months. RESULTS: The cost of PCABs for GERD was $3,240 more than PPIs, with an incremental cost-effectiveness ratio of $144,208/QALY. When evaluating GERD phenotypes separately, the incremental cost-effectiveness ratio was consistently over our willingness-to-pay threshold. One-way analyses showed the most influential parameters were PCAB cost and efficacy for heartburn-free days. Probabilistic sensitivity analysis favored PPIs 71.7% out of 100,000 iterations. Reducing one-week costs to below $91 would make PCABs a cost effective first-line strategy across all GERD phenotypes. DISCUSSION: Despite PCAB efficacy, PPIs are a cost-effective strategy for GERD treatment, and can be positioned ahead of PCAB escalation on this basis. Reducing PCAB costs or accepting a higher willingness-to-pay threshold would influence this finding, although PCABs may be favored in some current situations as evidenced by probabilistic sensitivity results.
- 10 February 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (10) , 2401-2410
Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease
INTRODUCTION: Potassium competitive acid blockers (PCABs) are superior to proton pump inhibitors (PPIs) for healing of Los Angeles (LA) class C/D erosive esophagitis and are approved for nonerosive gastroesophageal reflux disease (GERD) given their efficacy measured by heartburn-free days. However, they are more expensive than PPIs. We estimated the cost-effectiveness of PCABs compared with PPIs for the management of GERD. METHODS: A decision tree was constructed for the base case of a patient with GERD. We tested scenarios in which nonerosive reflux disease, LA A/B, or LA C/D esophagitis was present, comparing PCABs with PPIs as first-line therapy, including step up therapy and/or class switching if symptoms persisted. Using publicly available cost estimates, quality-adjusted life years (QALYs) were compared using a willingness-to-pay threshold of $100,000/QALY from a societal perspective at 6 months. RESULTS: The cost of PCABs for GERD was $3,240 more than PPIs, with an incremental cost-effectiveness ratio of $144,208/QALY. When evaluating GERD phenotypes separately, the incremental cost-effectiveness ratio was consistently over our willingness-to-pay threshold. One-way analyses showed the most influential parameters were PCAB cost and efficacy for heartburn-free days. Probabilistic sensitivity analysis favored PPIs 71.7% out of 100,000 iterations. Reducing one-week costs to below $91 would make PCABs a cost effective first-line strategy across all GERD phenotypes. DISCUSSION: Despite PCAB efficacy, PPIs are a cost-effective strategy for GERD treatment, and can be positioned ahead of PCAB escalation on this basis. Reducing PCAB costs or accepting a higher willingness-to-pay threshold would influence this finding, although PCABs may be favored in some current situations as evidenced by probabilistic sensitivity results.
- 25 February 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (10) , 2411-2422
Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis
INTRODUCTION: The adjunctive use of p53 immunohistochemistry has been proposed as a potential tool to improve risk stratification in Barrett's esophagus (BE) with conflicting results. We performed a systematic review and meta-analysis to evaluate the performance of p53 in predicting progression to advanced neoplasia (high-grade dysplasia [HGD] and esophageal adenocarcinoma [EAC]) among patients with BE. METHODS: We searched multiple databases for studies that evaluated the use of aberrant p53 in esophageal biopsies among patients with BE and reported progression rates to HGD/EAC. The outcomes were p53 test characteristics and incidence and risk ratio (RR) for progression to HGD/EAC in patients with and without aberrant p53 using random effects models. RESULTS: Among the 27 included studies, the proportion of patients with aberrant p53 expression at baseline was 20% (95% CI: 14%, 27%). The rate of progression with and without aberrant p53 was 8 per 100 person-years (95% CI: 6, 11) and 0.3 per 100 person-years (95% CI: 0.1, 0.6), respectively. Compared with patients without aberrant p53 expression, those with aberrant p53 had a higher risk for progression to HGD/EAC in cohort studies (RR = 10.2 [95% CI: 6.9, 15.0]) and case control studies (RR = 3.3 [95% CI: 2.5, 4.4]). The sensitivity for progression for non-dysplastic Barrett's esophagus and low-grade dysplasia/indefinite for dysplasia was 42% and 77% and specificity was 96% and 76%, respectively. DISCUSSION: While aberrant p53 expression has been associated with an increased risk of progression to advanced neoplasia in patients with BE undergoing surveillance, the diagnostic characteristics are suboptimal precluding uniform clinical adoption. Prospective studies with standardized grading protocols are needed to determine whether p53-guided surveillance strategies can meaningfully improve patient outcomes.
- 25 February 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (10) , 2411-2422
Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis
INTRODUCTION: The adjunctive use of p53 immunohistochemistry has been proposed as a potential tool to improve risk stratification in Barrett's esophagus (BE) with conflicting results. We performed a systematic review and meta-analysis to evaluate the performance of p53 in predicting progression to advanced neoplasia (high-grade dysplasia [HGD] and esophageal adenocarcinoma [EAC]) among patients with BE. METHODS: We searched multiple databases for studies that evaluated the use of aberrant p53 in esophageal biopsies among patients with BE and reported progression rates to HGD/EAC. The outcomes were p53 test characteristics and incidence and risk ratio (RR) for progression to HGD/EAC in patients with and without aberrant p53 using random effects models. RESULTS: Among the 27 included studies, the proportion of patients with aberrant p53 expression at baseline was 20% (95% CI: 14%, 27%). The rate of progression with and without aberrant p53 was 8 per 100 person-years (95% CI: 6, 11) and 0.3 per 100 person-years (95% CI: 0.1, 0.6), respectively. Compared with patients without aberrant p53 expression, those with aberrant p53 had a higher risk for progression to HGD/EAC in cohort studies (RR = 10.2 [95% CI: 6.9, 15.0]) and case control studies (RR = 3.3 [95% CI: 2.5, 4.4]). The sensitivity for progression for non-dysplastic Barrett's esophagus and low-grade dysplasia/indefinite for dysplasia was 42% and 77% and specificity was 96% and 76%, respectively. DISCUSSION: While aberrant p53 expression has been associated with an increased risk of progression to advanced neoplasia in patients with BE undergoing surveillance, the diagnostic characteristics are suboptimal precluding uniform clinical adoption. Prospective studies with standardized grading protocols are needed to determine whether p53-guided surveillance strategies can meaningfully improve patient outcomes.
- 5 August 2024
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 40 (6) , 442-448
Regurgitation, eructation, and supragastric belch: retrograde esophageal motility, disorders, and treatment
Purpose of review: This review describes pathologic conditions of retrograde flow into the esophagus along with recent therapeutic advances and treatment options. Recent findings: The esophagus facilitates anterograde and retrograde movement of contents, the latter of which is mediated by transient lower esophageal sphincter relaxations (TLESRs). Gastroesophageal reflux disease (GERD) often includes esophageal-specific symptoms such as heartburn or regurgitation. Volume regurgitation responds less frequently to acid suppression with proton pump inhibitors (PPIs) than heartburn, given its relationship with incompetence of the esophagogastric junction (EGJ) and increased frequency of TLESRs. Therefore, although the refluxate pH can be altered with PPIs, the frequency of reflux episodes is generally not reduced and surgical and endoscopic treatments may be favored. Other instances of abnormal retrograde esophageal flow respond better to medical therapy, or lifestyle interventions. Compared to gastric belching because of increased stomach distension, supragastric belching is caused by intake of air from pharynx into the esophagus followed by rapid expulsion of air. These conditions can be distinguished on esophageal tests such as high-resolution manometry and are likely to respond to behavioral modifications. Summary: Retrograde flow into the esophagus can be a normal occurrence, but diagnostic testing to distinguish causes can guide appropriate intervention.
- 5 August 2024
- Published by Wolters Kluwer Health in Current Opinion in Gastroenterology
- Vol. 40 (6) , 442-448
Regurgitation, eructation, and supragastric belch: retrograde esophageal motility, disorders, and treatment
Purpose of review: This review describes pathologic conditions of retrograde flow into the esophagus along with recent therapeutic advances and treatment options. Recent findings: The esophagus facilitates anterograde and retrograde movement of contents, the latter of which is mediated by transient lower esophageal sphincter relaxations (TLESRs). Gastroesophageal reflux disease (GERD) often includes esophageal-specific symptoms such as heartburn or regurgitation. Volume regurgitation responds less frequently to acid suppression with proton pump inhibitors (PPIs) than heartburn, given its relationship with incompetence of the esophagogastric junction (EGJ) and increased frequency of TLESRs. Therefore, although the refluxate pH can be altered with PPIs, the frequency of reflux episodes is generally not reduced and surgical and endoscopic treatments may be favored. Other instances of abnormal retrograde esophageal flow respond better to medical therapy, or lifestyle interventions. Compared to gastric belching because of increased stomach distension, supragastric belching is caused by intake of air from pharynx into the esophagus followed by rapid expulsion of air. These conditions can be distinguished on esophageal tests such as high-resolution manometry and are likely to respond to behavioral modifications. Summary: Retrograde flow into the esophagus can be a normal occurrence, but diagnostic testing to distinguish causes can guide appropriate intervention.
- 14 July 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (1)
Identification of gaps in the delivery of high-quality care of patients with eosinophilic esophagitis
Quality indicators (QIs) are standardized metrics that can be used to quantify health care delivery and identify important areas for practice improvement. Nine QIs pertaining to the diagnosis and management of eosinophilic esophagitis (EoE) were recently established. We therefore aimed to identify existing gaps in care using these QIs. This is a retrospective, multicenter study utilizing recently established EoE QIs to evaluate practice patterns among adult gastroenterologists in the diagnosis and management of EoE. Three patient cohorts of 30 patients each presenting with dysphagia, food impaction, and new diagnosis of EoE, respectively, were obtained, yielding 120 patients per site to assess for every QI. Summary statistics were reported across two main themes: diagnosis and management. Subsequent analysis of gaps in care was then performed. The domain of diagnosis of EoE (QI 1 and 2) had the most notable gap in care with only 55% of the presenting patients undergoing appropriate evaluation for EoE. The domain of management of EoE had overall higher QI fulfillment—however it also contained significant intra-category variation in care. Notably, while 79% of patients had clinical follow-up within 1 year from remission, only 54% underwent surveillance endoscopy within 2 years of remission. In contrast, 100% of patients with symptomatic strictures independent of histologic response underwent endoscopic dilation (QI 4). Management approaches for EoE are evolving and variation in care delivery exists. We identified significant gaps in both diagnosis of EoE especially amongst patients presenting with index food impaction and long term management of EoE, when retrospectively evaluating care patterns using newly established QIs. This is the first study of its kind to utilize these previously established QIs to objectively identify care gaps that exist in EoE amongst several institutions. These findings also highlight the importance of QIs and standardization of management of complex chronic diseases like EoE to help bridge these gaps and provide a framework to measure adherence to these best practices.
- 14 July 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (1)
Identification of gaps in the delivery of high-quality care of patients with eosinophilic esophagitis
Quality indicators (QIs) are standardized metrics that can be used to quantify health care delivery and identify important areas for practice improvement. Nine QIs pertaining to the diagnosis and management of eosinophilic esophagitis (EoE) were recently established. We therefore aimed to identify existing gaps in care using these QIs. This is a retrospective, multicenter study utilizing recently established EoE QIs to evaluate practice patterns among adult gastroenterologists in the diagnosis and management of EoE. Three patient cohorts of 30 patients each presenting with dysphagia, food impaction, and new diagnosis of EoE, respectively, were obtained, yielding 120 patients per site to assess for every QI. Summary statistics were reported across two main themes: diagnosis and management. Subsequent analysis of gaps in care was then performed. The domain of diagnosis of EoE (QI 1 and 2) had the most notable gap in care with only 55% of the presenting patients undergoing appropriate evaluation for EoE. The domain of management of EoE had overall higher QI fulfillment—however it also contained significant intra-category variation in care. Notably, while 79% of patients had clinical follow-up within 1 year from remission, only 54% underwent surveillance endoscopy within 2 years of remission. In contrast, 100% of patients with symptomatic strictures independent of histologic response underwent endoscopic dilation (QI 4). Management approaches for EoE are evolving and variation in care delivery exists. We identified significant gaps in both diagnosis of EoE especially amongst patients presenting with index food impaction and long term management of EoE, when retrospectively evaluating care patterns using newly established QIs. This is the first study of its kind to utilize these previously established QIs to objectively identify care gaps that exist in EoE amongst several institutions. These findings also highlight the importance of QIs and standardization of management of complex chronic diseases like EoE to help bridge these gaps and provide a framework to measure adherence to these best practices.
- 10 July 2024
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 36 (9) , e14861
Automated software‐derived supine baseline impedance is highly correlated with manual nocturnal baseline impedance for the diagnosis of GERD
Background: Mean nocturnal baseline impedance (MNBI) can improve diagnostic accuracy for gastroesophageal reflux disease (GERD), but must be manually calculated and is not routinely reported. We aimed to determine how automated software‐derived mean supine baseline impedance (MSBI), a potential novel GERD metric, is related to MNBI.Methods: Consecutively obtained pH‐impedance studies were assessed. Manually extracted MNBI was compared to MSBI using paired t‐test and Spearman's correlations.Key Results: The correlation between MNBI and MSBI was very high (ρ = 0.966, p < 0.01).Conclusions & Inferences: The ease of acquisition and correlation with MNBI warrant the routine clinical use and reporting of MSBI with pH‐impedance studies.
- 10 July 2024
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 36 (9) , e14861
Automated software‐derived supine baseline impedance is highly correlated with manual nocturnal baseline impedance for the diagnosis of GERD
Background: Mean nocturnal baseline impedance (MNBI) can improve diagnostic accuracy for gastroesophageal reflux disease (GERD), but must be manually calculated and is not routinely reported. We aimed to determine how automated software‐derived mean supine baseline impedance (MSBI), a potential novel GERD metric, is related to MNBI.Methods: Consecutively obtained pH‐impedance studies were assessed. Manually extracted MNBI was compared to MSBI using paired t‐test and Spearman's correlations.Key Results: The correlation between MNBI and MSBI was very high (ρ = 0.966, p < 0.01).Conclusions & Inferences: The ease of acquisition and correlation with MNBI warrant the routine clinical use and reporting of MSBI with pH‐impedance studies.
- 8 March 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 37 (6)
Measuring and improving quality in esophageal care and swallowing disorders
Summary: Evaluating clinical care through quality-related metrics is increasingly common. There are now numerous quality statements and indicators related to the medical management of benign and pre-malignant esophageal diseases. Expert consensus leveraging evidence-based recommendations from published society guidelines has been the most frequently used basis for developing esophageal quality statements. While surgical care of patients with esophageal malignancies, including squamous cell carcinoma, has also been developed, those related to benign esophageal disease now include domains of diagnosis, treatment, and monitoring for gastroesophageal reflux disease, eosinophilic esophagitis (EoE), achalasia, and Barrett’s esophagus (BE). Several recent studies evaluating adherence to quality metrics affirm substantial variation in practice patterns with opportunities for improvement in care across esophageal diseases. In particular, patient education regarding treatment options in achalasia, frequency of esophageal biopsies among patients with dysphagia to evaluate for EoE, and endoscopic evaluation within a BE segment are areas identified to have need for improvement. As the management of esophageal diseases becomes more complex and interdisciplinary, adherence to quality metrics may be a source of standardization and improvement in delivery and ultimately patient outcomes. Indeed, the development of national quality databases has resulted in a significant growth in the use of these metrics for quality improvement activities and may form the basis for future inclusion in quality reporting and payment programs.
- 8 March 2024
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 37 (6)
Measuring and improving quality in esophageal care and swallowing disorders
Summary: Evaluating clinical care through quality-related metrics is increasingly common. There are now numerous quality statements and indicators related to the medical management of benign and pre-malignant esophageal diseases. Expert consensus leveraging evidence-based recommendations from published society guidelines has been the most frequently used basis for developing esophageal quality statements. While surgical care of patients with esophageal malignancies, including squamous cell carcinoma, has also been developed, those related to benign esophageal disease now include domains of diagnosis, treatment, and monitoring for gastroesophageal reflux disease, eosinophilic esophagitis (EoE), achalasia, and Barrett’s esophagus (BE). Several recent studies evaluating adherence to quality metrics affirm substantial variation in practice patterns with opportunities for improvement in care across esophageal diseases. In particular, patient education regarding treatment options in achalasia, frequency of esophageal biopsies among patients with dysphagia to evaluate for EoE, and endoscopic evaluation within a BE segment are areas identified to have need for improvement. As the management of esophageal diseases becomes more complex and interdisciplinary, adherence to quality metrics may be a source of standardization and improvement in delivery and ultimately patient outcomes. Indeed, the development of national quality databases has resulted in a significant growth in the use of these metrics for quality improvement activities and may form the basis for future inclusion in quality reporting and payment programs.
- 4 December 2023
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 58 (9) , 857-864
Esophageal Function Testing Patterns in the Evaluation and Management of Lung Transplantation
Goals: We surveyed esophageal motility laboratories affiliated with adult pulmonary transplant centers to determine esophageal function testing (EFT) practices. Background: Gastroesophageal reflux and esophageal dysmotility are associated with worse lung transplant outcomes, yet no consensus guidelines for EFT exist in this population. Study: A deidentified online survey was sent to gastrointestinal motility laboratory directors of 49 academic and community-affiliated medical centers that perform lung transplants. Practice characteristics, including annual lung transplant volume and institutional EFT practices pre-lung transplantation and post-lung transplantation were queried. Respondents were categorized by transplant volume into small and large programs based on median annual volume. Results: Among 35 respondents (71% response rate), the median annual transplant volume was 37, and there were 18 large programs. Institutional EFT protocols were used pretransplant by 24 programs (68.6%) and post-transplant by 12 programs (34.2%). Among small and large programs, 52.9% and 72.2% always obtained high-resolution manometry before transplant, respectively. Endoscopy before transplant was performed more often in small programs (n=17, 100%) compared with large programs (n=15,83.3%). Pretransplant endoscopy (P=0.04), barium esophagram (PP=0.04) were more common than post-transplant. In contrast, post-transplant reflux monitoring off-therapy was more common than pretransplant (P=0.01). In general, pulmonologists direct referrals for EFT and gastroenterology consultation (n=28, 80.0%), with symptoms primarily prompting testing. Conclusions: In the absence of established guidelines, substantial variability exists in pretransplant and post-transplant EFT, directed by pulmonologists. Standardized EFT protocols and gastroenterologist-directed management of esophageal dysfunction has potential to improve lung transplant outcomes.
- 4 December 2023
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 58 (9) , 857-864
Esophageal Function Testing Patterns in the Evaluation and Management of Lung Transplantation
Goals: We surveyed esophageal motility laboratories affiliated with adult pulmonary transplant centers to determine esophageal function testing (EFT) practices. Background: Gastroesophageal reflux and esophageal dysmotility are associated with worse lung transplant outcomes, yet no consensus guidelines for EFT exist in this population. Study: A deidentified online survey was sent to gastrointestinal motility laboratory directors of 49 academic and community-affiliated medical centers that perform lung transplants. Practice characteristics, including annual lung transplant volume and institutional EFT practices pre-lung transplantation and post-lung transplantation were queried. Respondents were categorized by transplant volume into small and large programs based on median annual volume. Results: Among 35 respondents (71% response rate), the median annual transplant volume was 37, and there were 18 large programs. Institutional EFT protocols were used pretransplant by 24 programs (68.6%) and post-transplant by 12 programs (34.2%). Among small and large programs, 52.9% and 72.2% always obtained high-resolution manometry before transplant, respectively. Endoscopy before transplant was performed more often in small programs (n=17, 100%) compared with large programs (n=15,83.3%). Pretransplant endoscopy (P=0.04), barium esophagram (PP=0.04) were more common than post-transplant. In contrast, post-transplant reflux monitoring off-therapy was more common than pretransplant (P=0.01). In general, pulmonologists direct referrals for EFT and gastroenterology consultation (n=28, 80.0%), with symptoms primarily prompting testing. Conclusions: In the absence of established guidelines, substantial variability exists in pretransplant and post-transplant EFT, directed by pulmonologists. Standardized EFT protocols and gastroenterologist-directed management of esophageal dysfunction has potential to improve lung transplant outcomes.